New Studies Show Paxlovid May Not Significantly Benefit Seniors

Source: Time, MSN

Recent studies suggest that Paxlovid, an antiviral medication used to treat COVID-19, may not significantly benefit vaccinated seniors. Research conducted in Ontario, Canada, found that among vaccinated older adults, Paxlovid did not show a statistically significant reduction in COVID-19 hospitalizations or mortality rates. This contrasts with earlier studies that demonstrated the drug’s effectiveness in unvaccinated populations.

The findings indicate that while Paxlovid may still be useful for high-risk individuals, its benefits for vaccinated seniors are less pronounced than initially thought. Further research is needed to understand its impact on different subgroups and to guide treatment decisions for older adults.

This is not surprising that the pill created to offset the effectiveness of Ivermectin and other preventative remedies, has been proven to not significantly benefit the very group of people it was targeted to help. More studies are needed to prove if Paxlovid is effective at all.

The Biden Administration pushed Paxlovid and less than 100 days into the Trump administration and less than a week into Robert F. Kennedy’s tenure as Health and Human Services Director new science is being released that discredits the effectiveness of Paxlovid.

If you are tired of the jab and were not relieved by Paxlovid schedule with Frontline Doctors and get the truth about preventative and symptomatic treatment options which are back by the approval of 100,000 and thousands of patients and providers. We are thankful to be able to express the truth again without threat.